Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Enzalutamide

FDA-approved product (capsule, oral), marketed as Enzalutamide, Xtandi.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Enzalutamide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Metastatic prostate cancer
  • Neoplasm
  • Prostate adenocarcinoma
  • Prostate cancer
  • Prostate carcinoma
  • Prostate neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Anti-androgens
FDA pharmacologic class
Androgen Receptor Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Enzalutamide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Enzalutamide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

    NCT07570979 · start 2026-05-25

    Registered record
    Registry ID
    NCT07570979
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC)
    Interventions
    INR731; Enzalutamide; Abiraterone; Androgen deprivation therapy (ADT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-25
    Completion
    2030-06-03
    Enrolment
    208

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC)
    InterventionINR731; Enzalutamide; Abiraterone; Androgen deprivation therapy (ADT)
    PhasePhase 1
    Registry statusRecruiting

  • A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

    NCT07311694 · start 2026-02-02

    Registered record
    Registry ID
    NCT07311694
    Conditions
    PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
    Interventions
    HRS-4357 injection; Enzalutamide；Abiraterone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2026-02-02
    Completion
    2028-12
    Enrolment
    370

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
    InterventionHRS-4357 injection; Enzalutamide；Abiraterone
    PhasePhase 3
    Registry statusRecruiting

  • Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

    NCT07172126 · start 2025-09

    Registered record
    Registry ID
    NCT07172126
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    TQB3201 tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Not yet recruiting
    Start
    2025-09
    Completion
    2028-12
    Enrolment
    291

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionTQB3201 tablets
    PhasePhase 1 / Phase 2
    Registry statusNot yet recruiting

  • The COSMYC Trial (COmbined Suppression of MYC)

    NCT06922318 · start 2025-08-19

    Registered record
    Registry ID
    NCT06922318
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    ZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-08-19
    Completion
    2031-08-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    InterventionZEN-3694; Testosterone cypionate; Enzalutamide; Luteinizing hormone-releasing hormone (LHRH) analogue
    PhasePhase 2
    Registry statusRecruiting

  • Castrate Resistant Prostate Cancer Enhertu Therapy

    NCT06610825 · start 2025-03-05

    Registered record
    Registry ID
    NCT06610825
    Conditions
    Prostate Cancer Metastatic; Prostate Cancer; CRPC
    Interventions
    Enhertu
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-03-05
    Completion
    2028-10
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic; Prostate Cancer; CRPC
    InterventionEnhertu
    PhasePhase 2
    Registry statusRecruiting

  • Impact of New Hormonotherapy Drugs in Prostatic Cancer on the Risk of Cardiovascular Events : a Pharmacoepidemiology Study Using the French Health Care Claims Database

    NCT06902441 · start 2025-01-07

    Registered record
    Registry ID
    NCT06902441
    Conditions
    Prostate Cancer
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2025-01-07
    Completion
    2025-06-30
    Enrolment
    52,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer

    NCT06236139 · start 2024-11-26

    Registered record
    Registry ID
    NCT06236139
    Conditions
    Metastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    Interventions
    Anti-STEAP1 CAR T-cells; Biopsy Procedure; Biospecimen Collection; Bone Scan; Computed Tomography; Cyclophosphamide; Echocardiography Test; Enzalutamide; Fludarabine; Leukapheresis; Magnetic Resonance Imaging; Multigated Acquisition Scan; Positron Emission Tomography
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2024-11-26
    Completion
    2027-03-30
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-Resistant Prostate Carcinoma; Metastatic Prostate Adenocarcinoma; Stage IVB Prostate Cancer AJCC v8
    InterventionAnti-STEAP1 CAR T-cells; Biopsy Procedure; Biospecimen Collection; Bone Scan +9 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)

    NCT06496581 · start 2024-09-12

    Registered record
    Registry ID
    NCT06496581
    Conditions
    Prostate Cancer Metastatic
    Interventions
    177Lu-PMSA-617; Standard of Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-09-12
    Completion
    2039-08-01
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer Metastatic
    Intervention177Lu-PMSA-617; Standard of Care
    PhasePhase 3
    Registry statusRecruiting

  • The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

    NCT06520345 · start 2024-07-26

    Registered record
    Registry ID
    NCT06520345
    Conditions
    Metastatic Castration-resistant Prostate Cancer
    Interventions
    177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-07-26
    Completion
    2030-12
    Enrolment
    520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer
    Intervention177Lu-TLX591; Enzalutamide; Abiraterone; Docetaxel
    PhasePhase 3
    Registry statusRecruiting

  • Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban

    NCT05339672 · start 2024-07-01

    Registered record
    Registry ID
    NCT05339672
    Conditions
    Drug-drug Interaction
    Interventions
    Blood sampling - Pharmacokinetic assessment
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2024-07-01
    Completion
    2024-08-31
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction
    InterventionBlood sampling - Pharmacokinetic assessment
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    NCT06136650 · start 2023-12-18

    Registered record
    Registry ID
    NCT06136650
    Conditions
    Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    Interventions
    Opevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone; Abiraterone acetate; Prednisone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2023-12-18
    Completion
    2030-12-02
    Enrolment
    1,314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms
    InterventionOpevesostat; Dexamethasone; Fludrocortisone acetate; Hydrocortisone +3 more
    PhasePhase 3
    Registry statusRecruiting

  • Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

    NCT05743621 · start 2023-11-20

    Registered record
    Registry ID
    NCT05743621
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    TVB-2640; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-11-20
    Completion
    2029-01-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionTVB-2640; Enzalutamide
    PhasePhase 1
    Registry statusRecruiting

  • An Open Label Phase II Study of First-Line Maintenance Enzalutamide Following Docetaxel Plus Androgen-Deprivation Therapy in Patients With Previously-Untreated, Metastatic, Castration-Naive Prostatic Adenocarcinoma

    NCT06015321 · start 2023-10-01

    Registered record
    Registry ID
    NCT06015321
    Conditions
    Prostatic Adenocarcinoma
    Interventions
    Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2023-10-01
    Completion
    2026-04-30
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Adenocarcinoma
    InterventionEnzalutamide
    PhasePhase 2
    Registry statusUnknown

  • Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPC

    NCT05771896 · start 2023-09

    Registered record
    Registry ID
    NCT05771896
    Conditions
    Metastatic Prostate Cancer
    Interventions
    Darolutamide; Radium-223
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-09
    Completion
    2029-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Prostate Cancer
    InterventionDarolutamide; Radium-223
    PhasePhase 3
    Registry statusWithdrawn

  • Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC

    NCT05393791 · start 2022-11-10

    Registered record
    Registry ID
    NCT05393791
    Conditions
    Prostatic Neoplasms, Castration-Resistant
    Interventions
    Patient-specific adaptive therapy; Abiraterone acetate; Enzalutamide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-11-10
    Completion
    2027-11-10
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Neoplasms, Castration-Resistant
    InterventionPatient-specific adaptive therapy; Abiraterone acetate; Enzalutamide
    PhasePhase 2
    Registry statusRecruiting